<DOC>
	<DOCNO>NCT01830699</DOCNO>
	<brief_summary>To date trial perform look whether intra-bursal injection IL-1 antagonist provide pain relief similar corticosteroid injection . The subcutaneous injection anakinra , IL-1 receptor antagonist , patient shoulder pain due rotator cuff tendonitis subacromial bursitis efficacious relieve pain information present case series letter editor format , validity result would require additional testing [ Omoigui S , et al . 2004 ] . Based mainly data intra-articular administration anakinra , adverse trend outcomes safety suggest intra-bursal injection rilonacept carry increase risk adverse event . The purpose trial compare improvement pain function patient clinical symptom sign subacromial bursitis rilonacept vs. corticosteroid injection ( standard care ) .</brief_summary>
	<brief_title>Rilonacept ( Arcalyst ® ) Treatment Subacromial Bursitis</brief_title>
	<detailed_description>Background : Subacromial bursitis inflammatory condition typically trigger altered rotator cuff mechanic . One mainstays therapy corticosteroid injection . Given inflammatory nature subacromial bursitis couple prominence interleukin-1 ( IL-1 ) beta histopathologic assessment resect subacromial bursa , target anti-IL-1 therapy would attractive alternative corticosteroid injection . Hypothesis : One intra-bursal injection IL-1 trap rilonacept ( Arcalyst ® ) , currently FDA approve treatment cryopyrin associate periodic syndrome ( CAPS ) , non-inferior intra-bursal corticosteroid injection 4 week post-procedure . Methods : This study prospective trial last total 4 week . Patients typical symptom sign subacromial bursitis randomize either corticosteroid injection prepare usual fashion clinic vs. injection rilonacept . Prior injection either medication patient complete QuickDASH Questionnaire provide verbal pain score 0 10 . The Quick DASH Questionnaire verbal pain score complete within 2 duty day injection , 2 week injection , 4 week injection phone . Primary Outcome : Primary outcome improvement QuickDASH . Secondary outcome improvement verbal pain score monitoring infection complication rilonacept administration .</detailed_description>
	<mesh_term>Bursitis</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>At least 18 year age old minimum recent history ( 3 day worth ) shoulder pain moderate severe tenderness palpation subacromial bursa . Allergies lidocaine , marcaine , kenalog . Allergies rilonacept Flare active inflammatory arthritis ( flare Rheumatoid Arthritis ) Gout Pseudogout attack shoulder subacromial tenderness Active infection Actively receive chemotherapy , radiation therapy , anticipate surgery neoplasia Active myocardial infarction Clinical and/or radiographic evidence fracture ( clavicular , humeral , ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rilonacept</keyword>
	<keyword>Subacromial Bursitis treatment</keyword>
	<keyword>Corticosteroid Injection</keyword>
</DOC>